![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 13, 2020 4:55:08 PM
I believe that all in a trial should get the drug, the control can easily be all the others in similar circumstances,
but I doubt if the FDA and other regulators will treat it that way.
I do believe, that based on solid evidence of PLX cells having a beneficial effect in moderating the side effects of pneumonia, and now the seemingly good results with Covid patients, we very likely have an important therapeutic tool to offer.
Even if we don't get direct reports from Pluristem, the continued interest of doctors and patients is the sort of "anecdotal" evidence that strongly suggests good results. After all, doctors do talk to each other about what works, especially now.
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM